FibroGen Inc. appears to have a potential blockbuster on its hands with its anti-connective tissue growth factor (CTGF) antibody pamrevlumab (FG-3019) after Phase II data suggested its potential as a monotherapy and possibly in combination with current treatments for idiopathic pulmonary fibrosis, a disease which has a poorer prognosis than many cancers.
FibroGen Hails 'Milestone' IPF Data, Phase III And Partners Beckon
Phase II data for FibroGen's first-in-class therapy for idiopathic pulmonary fibrosis panrevlumab has sent its shares soaring and could have potential partners scrambling.
